1xbet APK Pharmaceutical Co., Ltd.
1xbet APK Holdings Co., Ltd.
Pharmaceuticals
February 1, 2011
1xbet APK Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
Tokyo, Japan, February 1, 2011 -- 1xbet APK Pharmaceutical Co., Ltd. today announced the initiation of the phase II clinical trial of OCV-101*for pancreatic cancer in Japan. OCV-101 is an angiogenesis inhibitor which has been co-developed by OncoTherapy Science, Inc. and 1xbet APK Pharmaceutical.
- *OCV-101: 1xbet APKmally named OTS11101. The development code was changed from the start of this trial.
OCV-101 X is a therapeutic cancer vaccine targeting the endothelial cells of new blood vessels feeding tumors. The phase II clinical trial will evaluate the efficacy and safety of OCV-101 1xbet APK the treatment of patients with unresectable advanced pancreatic cancer and recurrent pancreatic cancer. This trial will be conducted in eight medical institutions in Japan.
Based on its corporate philosophy of '1xbet APK-people creating new products for better health worldwide,' 1xbet APK Pharmaceutical is dedicated to contributing to the health of people around the world.
Latest Pharmaceutical Bus1xbet APKess related News Releases